Cargando…
Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022
As atherosclerosis begins in childhood, early diagnosis and treatment of familial hypercholesterolemia (FH) is considered necessary. The basic diagnosis of pediatric FH (under 15 years of age) is based on hyper-low-density lipoprotein (LDL) cholesterolemia and a family history of FH; however, in thi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Atherosclerosis Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164603/ https://www.ncbi.nlm.nih.gov/pubmed/36682777 http://dx.doi.org/10.5551/jat.CR006 |
_version_ | 1785038105036718080 |
---|---|
author | Harada-Shiba, Mariko Ohtake, Akira Sugiyama, Daisuke Tada, Hayato Dobashi, Kazushige Matsuki, Kota Minamino, Tetsuo Yamashita, Shizuya Yamamoto, Yukiyo |
author_facet | Harada-Shiba, Mariko Ohtake, Akira Sugiyama, Daisuke Tada, Hayato Dobashi, Kazushige Matsuki, Kota Minamino, Tetsuo Yamashita, Shizuya Yamamoto, Yukiyo |
author_sort | Harada-Shiba, Mariko |
collection | PubMed |
description | As atherosclerosis begins in childhood, early diagnosis and treatment of familial hypercholesterolemia (FH) is considered necessary. The basic diagnosis of pediatric FH (under 15 years of age) is based on hyper-low-density lipoprotein (LDL) cholesterolemia and a family history of FH; however, in this guideline, to reduce overlooked cases, “probable FH” was established. Once diagnosed with FH or probable FH, efforts should be made to promptly provide lifestyle guidance, including diet. It is also important to conduct an intrafamilial survey, to identify family members with the same condition. If the level of LDL-C remains above 180 mg/dL, drug therapy should be considered at the age of 10. The first-line drug should be statin. Evaluation of atherosclerosis should be started using non-invasive techniques, such as ultrasound. The management target level is an LDL-C level of less than 140 mg/dL. If a homozygous FH is suspected, consult a specialist and determine the response to pharmacotherapy with evaluating atherosclerosis. If the response is inadequate, initiate lipoprotein apheresis as soon as possible. |
format | Online Article Text |
id | pubmed-10164603 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Japan Atherosclerosis Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-101646032023-05-09 Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022 Harada-Shiba, Mariko Ohtake, Akira Sugiyama, Daisuke Tada, Hayato Dobashi, Kazushige Matsuki, Kota Minamino, Tetsuo Yamashita, Shizuya Yamamoto, Yukiyo J Atheroscler Thromb Correspondence As atherosclerosis begins in childhood, early diagnosis and treatment of familial hypercholesterolemia (FH) is considered necessary. The basic diagnosis of pediatric FH (under 15 years of age) is based on hyper-low-density lipoprotein (LDL) cholesterolemia and a family history of FH; however, in this guideline, to reduce overlooked cases, “probable FH” was established. Once diagnosed with FH or probable FH, efforts should be made to promptly provide lifestyle guidance, including diet. It is also important to conduct an intrafamilial survey, to identify family members with the same condition. If the level of LDL-C remains above 180 mg/dL, drug therapy should be considered at the age of 10. The first-line drug should be statin. Evaluation of atherosclerosis should be started using non-invasive techniques, such as ultrasound. The management target level is an LDL-C level of less than 140 mg/dL. If a homozygous FH is suspected, consult a specialist and determine the response to pharmacotherapy with evaluating atherosclerosis. If the response is inadequate, initiate lipoprotein apheresis as soon as possible. Japan Atherosclerosis Society 2023-05-01 2023-01-20 /pmc/articles/PMC10164603/ /pubmed/36682777 http://dx.doi.org/10.5551/jat.CR006 Text en 2023 Japan Atherosclerosis Society https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) |
spellingShingle | Correspondence Harada-Shiba, Mariko Ohtake, Akira Sugiyama, Daisuke Tada, Hayato Dobashi, Kazushige Matsuki, Kota Minamino, Tetsuo Yamashita, Shizuya Yamamoto, Yukiyo Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022 |
title | Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022 |
title_full | Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022 |
title_fullStr | Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022 |
title_full_unstemmed | Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022 |
title_short | Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022 |
title_sort | guidelines for the diagnosis and treatment of pediatric familial hypercholesterolemia 2022 |
topic | Correspondence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164603/ https://www.ncbi.nlm.nih.gov/pubmed/36682777 http://dx.doi.org/10.5551/jat.CR006 |
work_keys_str_mv | AT haradashibamariko guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022 AT ohtakeakira guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022 AT sugiyamadaisuke guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022 AT tadahayato guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022 AT dobashikazushige guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022 AT matsukikota guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022 AT minaminotetsuo guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022 AT yamashitashizuya guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022 AT yamamotoyukiyo guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022 |